Context: Depleted nitric oxide levels in the human body play a major role in cardiovascular disease pathogenesis. Inorganic nitrate/nitrite (rich dietary sources include beetroot and spinach) can act as a nitric oxide donor because nitrate/nitrite can be metabolized to produce nitric oxide. Objective: This review and metaanalysis sought to investigate the role of inorganic nitrate/nitrite in preventing or treating cardiovascular disease risk factors in humans. Data Sources: Electronic databases, including Medline, Embase, Cumulative Index to Nursing and Allied Health Literature, Cochrane, and Scopus, were searched. Data Extraction: Experimental trials examining the effect of oral inorganic nitrate/nitrite intake on cardiovascular disease risk factors were included for systematic analysis. Results: Thirty-four studies were included for qualitative synthesis, 23 of which were eligible for meta-analysis. Included studies measured the following outcomes: blood pressure, endothelial function, arterial stiffness, platelet aggregation, and/or blood lipids. Inorganic nitrate intake was found to significantly reduce resting blood pressure (systolic blood pressure: À4.80 mmHg, P < 0.0001; diastolic blood pressure: À1.74 mmHg, P ¼ 0.001), improve endothelial function (flow-mediated dilatation: 0.59%, P < 0.0001), reduce arterial stiffness (pulse wave velocity: À0.23 m/s, P < 0.0001; augmentation index: À2.1%, P ¼ 0.05), and reduce platelet aggregation by 18.9% (P < 0.0001). Conclusions: Inorganic nitrate consumption represents a simple strategy for targeting cardiovascular disease risk factors. Future studies investigating the long-term effects of inorganic nitrate on cardiovascular disease outcomes are warranted.
INTRODUCTION
Cardiovascular disease (CVD) due to atherosclerosis is one of the leading causes of morbidity and mortality in the world.
1,2 Elevated blood pressure (BP) is one of the major contributing risk factors for atherosclerosis and CVD; however, a 10-mmHg reduction in systolic BP (SBP) is associated with a reduced risk of CVD events, including coronary heart disease, stroke, and heart failure. 3 However, the pathogenesis of atherosclerosis is complex and influenced by a dynamic interplay of risk factors, including endothelial dysfunction, arterial stiffness, platelet aggregation, and dyslipidemia. 4 Nitric oxide (NO) is a potent vasodilator and vascular endothelium relaxant, and a reduction in the availability and/or bioactivity of NO is linked to the development of hypertension, endothelial dysfunction, atherosclerosis, and CVD. [5] [6] [7] [8] Under optimum functioning conditions, the human body produces approximately 70% of required NO endogenously by NO synthase enzymes. 9, 10 However, diet can provide an alternative source of NO, and an increasing body of evidence indicates that dietary nitrate intakes contribute substantially to NO availability in the human body via the nitrate-nitrite-NO pathway. [11] [12] [13] Nitrate is widely available in the diet, with vegetables sources accounting for approximately 60%-80% total daily consumption. 11, 14 Nitrate-rich plant sources include green leafy vegetables, celery, and beetroot, because nitrate tends to accumulate in the leaves, stems, and roots of plants. 15, 16 With a bioavailability of 100% in the human body, inorganic nitrate can raise plasma nitrate concentrations for up to 5-6 hours after ingestion. 17, 18 Although approximately 75% of this nitrate is excreted at the kidneys, 25% is extracted by the salivary glands. 17 As part of the nitrate-nitrite-NO pathway, salivary nitrate is reduced to nitrite via bacteria in the oral cavity. 19, 20 This nitrite-rich saliva is swallowed and further reduced in the acidic stomach to nitrogen oxides, including NO. 20 Nitrite can also be reduced to NO along the physiological oxygen gradient of the circulatory system; for example, deoxygenated hemoglobin in the peripheral circulation can act as a nitrite reductase for NO production in the blood vessels. 21, 22 Further, this process is thought to have a major role in maintaining vascular health through the generation of NO in the blood vessels. 21, 23 Currently the acceptable daily limit for nitrate is 3.7 mg/kg of body weight (BW)/day, which is equivalent to approximately 222 mg/day for a 60-kg adult. 24 However, it is worth noting that cardioprotective dietary patterns rich in vegetables, such as the Mediterranean and Dietary Strategies to Prevent Hypertension (DASH) diets, are also naturally high in dietary nitrate, providing approximately 174-1222 mg of nitrate per day, a level of intake that far exceeds the intake on an average Western diet, which provides approximately 75 mg/day. [25] [26] [27] There is an increasing need within the scientific community for an unbiased, comprehensive investigation into the role of inorganic nitrate in relation to a variety of CVD risk factors and related outcomes to further consolidate the impact of dietary nitrate as a potential novel food solution to this major health problem. Therefore, the primary aim of this systematic review and meta-analysis was to investigate the effect of inorganic nitrate and nitrite on BP. Secondary aims focus on other CVD risk factors, including endothelial function, arterial stiffness, platelet aggregation, and blood lipids.
METHODS
A protocol was published in PROSPERO (http:// www.crd.york.ac.uk/PROSPERO/display_record.asp?ID¼ CRD42015027290). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were consulted throughout the execution of this systematic review. Participants, interventions, comparators, outcomes, study design (PICOS) criteria were defined (Table 1) .
Inclusion criteria
Types of participants. This review considered studies that included adults of all ages (18 years and older). Participants included a general healthy population; however, some studies included participants with cardiovascular risk factors, including hypertension, overweight and obesity, and hypercholesterolemia. Participant groups with specific diagnosed chronic diseases, including CVD, peripheral artery disease, chronic obstructive pulmonary disease, and diabetes, were excluded.
Types of studies. Experimental human studies such as randomized controlled trials (RCTs), quasi-RCTs, matched-pairs RCTs, cross-over trials, and pre-and poststudies were included. Included studies were those that looked at the oral consumption of inorganic nitrates and/or nitrites in a measured or estimated dose Research studies that investigated the action of drug-related products or had an exercise tolerance focus were excluded. In addition, nitrate interventions administered in conjunction with extreme environmental manipulation (eg, high temperatures, exposure to ultraviolet lights, hypoxic conditions) were not included for review.
Types of outcomes. This systematic review and metaanalysis aimed to include articles that reported on a variety of CVD risk factors. The primary outcome of interest was BP, and the secondary outcomes included endothelial function, arterial stiffness, platelet aggregation, and plasma lipids.
For the primary outcome, studies measured resting BP and/or ambulatory BP as per established protocols. For measurements of endothelial function, included studies measured flow-mediated dilatation (FMD), in which a reduction in FMD represents a reduction in endothelial function. 28 For measurements of arterial stiffness, included studies used noninvasive measurements, including pulse wave velocity (PWV) and augmentation index (AIx), for which higher readings indicate increased arterial stiffness. 29, 30 Platelet aggregation is an indicator of blood clotting capacity. Included studies measured platelet aggregation in response to platelet agonist. 31 Plasma lipid parameters of interest included total cholesterol, triglycerides (TGs), low-density lipoproteins (LDLs), and high-density lipoproteins (HDLs).
Search strategy
A systematic search of 5 electronic databases (Medline, Embase, Cumulative Index to Nursing and Allied Health Literature, Cochrane, and Scopus) was undertaken to identify published studies in the English language dated from inception of the database to November 2016.
The search was conducted based on predefined key search terms (Table S1 in the Supporting Information online). The relevance of the studies were evaluated by 2 independent reviewers based on the article titles and abstracts. Full articles were retrieved for studies that were found to meet the selection criteria or those that were unclear. When a study was excluded, the reason for exclusion was recorded. The reference lists of included studies were also searched to identify other studies relevant for inclusion. At each stage, the article was either discarded or moved to the next phase once full agreement was reached between reviewers. In the case of disagreement, the article was evaluated by a third investigator, and a final decision was reached by consensus.
Included studies were assessed post hoc for metaanalysis eligibility. Studies relevant for meta-analysis inclusion had measured change in BP, FMD, PWV, AIx, and/or platelet aggregation. If the required data had not been reported fully in the published article, the corresponding authors were contacted for additional information to maximize the number of studies for inclusion. Studies relevant for inclusion included mean change from baseline for intervention arms with a measurement of error (standard deviation [SD] , standard error of the mean [SEM], or 95% confidence interval [95%CI]).
Study quality
All included studies were assessed for methodological quality by 2 reviewers using the Academy of Nutrition and Dietetics quality criteria checklist 32 to identify the strength of research design, relevance, and validity. Sources of bias, such as population selection and blinding, were also considered. The reviewers used the checklist to assign an overall quality rating to the study of positive, neutral, or negative. Discrepancies in study quality rating between reviewers were resolved either by discussion between the 2 reviewers or, if necessary, by further discussion with a third reviewer.
Data extraction and synthesis
Data extraction was conducted by 1 reviewer and checked for accuracy and consistency by a second reviewer. Study design and participant characteristics were extracted, as well as data in relation to study outcomes. Data on the effect of inorganic nitrates and nitrites in relation to CVD risk factors were extracted. Data were synthesized in narrative form to identify the direction of effect, strength of effect, and consistency of effect across the included studies.
Meta-analysis was conducted to quantify the effect of inorganic nitrate on resting BP, ambulatory BP, PWV, AIx, and platelet aggregation. Quantitative data analysis was based on the absolute mean differences. On occasions when these data were not provided, mean differences were calculated, and the SDs of the mean differences were calculated, assuming a conservative correlation of 0.6 between time points. 33 Meta-analysis was not appropriate for plasma lipids because of too few comparable observations (n 2) and high heterogeneity.
Quantitative meta-analysis statistics
Random-effects meta-analyses were conducted to provide a more conservative estimate of the pooled effect size. Heterogeneity among the trials was quantified using I 2 , 34 which is the measure of percentage inconsistency across studies that is present due to heterogeneity. Meta-analyses were conducted using the "metan" command and meta-regression analyses was conducted using the "metareg" command installed in Stata 14.2 (StataCorp, College Station, TX, USA). Data are presented as mean differences and 95%CI. Forest plots were generated for graphical presentations of the outcomes. Funnel plots (and contour-enhanced funnel plots) were generated to identify potential publication bias and selective reporting bias. Subgroup analyses were conducted to evaluate whether outcomes were influenced by the source of nitrate (eg, KNO 3 vs beetroot vs spinach), participant population type (healthy vs patient), and study quality rating (neutral vs positive). Random-effects meta-regression analysis was conducted to explore between-study heterogeneity and to identify whether effect sizes were associated with the daily dose of inorganic nitrate (mg), the study duration ( 24 h vs >24 h), year of publication, and study participant characteristics (mean age [y], ratio of male-to-female participants, and body mass index [BMI; kg/m 2 ]).
RESULTS

Main search
A total of 14 090 articles were identified through the initial literature search and through additional searches, including manual reference list searching. Once duplicates (n ¼ 4700) were removed, 9390 article titles and abstracts were screened. Seventy-seven articles were identified for full-text review, from which 34 studies were included for systematic qualitative analysis ( Figure 1) . 17, 26, All 34 included studies were experimental studies, 5 of which each included 2 interventions relevant to the review, leading to the inclusion of 39 interventions in total. 17, 48, 53, 63, 65 Participant characteristics A total of 813 participants were included in this review (mean no. of participants per study, 20; range, 7-69). Approximately 51% (n ¼ 416/813) of the total participant population were male. The age of study participants was highly variable, with the mean age ranging from 20 to 72.5 years in the included studies. The majority of the included studies focused on generally healthy participants; however, 5 studies included participants with high BP, and 1 study investigated participants with hypercholesterolemia. 36, 40, 41, 43, 52, 64 Twenty-two of the included studies were conducted in the United Kingdom,  17,37,38,46-49,52-54,56,57,61,63-66 5  were conducted in Australia, [40] [41] [42] [43] 58 and 4 were conducted in the United States. 39, 44, 55, 59 The remaining studies were conducted in Germany (n ¼ 3), 45, 60, 62 the Netherlands (n ¼ 2), 50, 51 Denmark (n ¼ 1), 26 Japan (n ¼ 1), 35 and Iran (n ¼ 1). 50 investigated the effect of nitrate (800 mg) from common sources, including BJ and NaNO 3 solution; however, this 4-arm intervention trial also studied the effect of a fresh arugula beverage and a fresh spinach beverage. 50 Intervention duration periods ranged from 2 hours to 70 days. 17, 39, 44 The washout period for crossover studies ranged from 3 days to 28 days. 38, 54, 65 The main study characteristics are presented in Table 2 . 17, 26, Outcomes Included studies focused on CVD risk factors such as BP (n ¼ 33), 17, 26, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] 63, 64, 66 endothelial function (n ¼ 12), 17, 36, 38, 42, 45, [51] [52] [53] 60, 62, 64 arterial stiffness (n ¼ 10), 38, 41, 44, 47, 51, 52, 55, 60, 64 blood lipids (n ¼ 4), 36, 47, 51, 64 and platelet aggregation (n ¼ 3). 61, 64, 65 Resting BP was generally measured by an automated BP device after at least 5 minutes of rest in a seated position. 17, [35] [36] [37] [38] [39] [40] 42, 44, 46, 49, 53, 54, [56] [57] [58] [59] [60] [62] [63] [64] 66 Ambulatory BP was also commonly measured using a BP monitor that had been fitted to the participant and set to automatically measure BP in 20-60-minute intervals. 40, 41, 43, 46, 47, 49, 51 Flow-mediated dilatation was measured noninvasively using ultrasonic imaging techniques to assess the diameter of the brachial artery. 17, 36, 38, 42, 44, 45, 51, 53, 60, 62, 64 Flow-mediated dilatation
Pulse wave velocity and AIx were measured using noninvasive technologies that measured the change in artery pressure or differences in artery densities. 38, 41, 44, 47, 51, 55, 57, 58, 60, 64 Electrical impedance technology was used to measure platelet aggregation in response to a range of platelet agonists, including collagen, adenosine diphosphate (ADP), and epinephrine. 61, 64, 65 The plasma lipid parameters measured across relevant studies included plasma total cholesterol, TGs, LDLs, and HDLs. 36, 47, 51, 64 Study quality
The quality ratings of included studies are reported in Table 2 . Overall, 17 of 34 studies were rated as positive in quality, indicating that the validity and methodologies of these studies were strong. 36-38,40-42,44,47-52, 54,57,58,64 The remaining 17 studies were rated neutral in quality, an outcome most frequently due to either the participant selection criteria not being clearly stated or due to concerns that the study participants were not a true representative sample of the target population. 17, 26, 35, 39, 43, 45, 46, 53, 55, 56, [59] [60] [61] [62] [63] 65, 66 It was rare that studies did not clearly have comparable study groups (n ¼ 1) 61 or that the study interventions were not clearly described (n ¼ 2). 26, 62 However, methods of handling participant withdrawal were not always described (n ¼ 12), 17, 26, 39, 46, 48, 55, 56, 60, 61, 63, 65, 66 and blinding of study participants or investigators was not always clearly implemented when possible (n ¼ 13). 17, 39, 41, 42, [45] [46] [47] 49, 51, [57] [58] [59] 61, 63 Adverse events Only 18 of the included studies addressed adverse events encountered with nitrate/nitrite supplementation. Four of these studies found study interventions to have no adverse effects 38, 43, 53, 62 ; however, DeVan et al. 44 reported mild adverse events, such as headaches, nausea, fatigue, dizziness, and dry mouth in study participants (64% on the placebo, 73% on the 80 mg nitrite/day, and 100% on the 160 mg nitrite/day reported adverse events). 44 Another intervention by Kapil et al 53 reported gastritis in a participant who did not eat a snack with the KNO 3 capsule. 53 Jonvik et al 50 reported events of gastrointestinal discomfort in 3 of 18 participants after consumption of the arugula or spinach beverage. 50 Eleven studies found events of beeturia and/or red stools in participants consuming BJ, 17, 39, [47] [48] [49] 52, 54, 63, 64 which is a well-known and harmless side effect of ingesting beetroot and other foods colored with the red pigment betacyanin. 67 
Qualitative results
Blood pressure. Seventeen of the studies that measured BP investigated the acute ( 24 Bond et al 39 found BJ consumption (%750 mg of nitrate) led to statistically significant reductions in resting SBP (À5.7 mmHg; 95%CI, À7.68 to À3.72 mmHg; P < 0.05) and MAP (À4.3 mmHg; 95%CI, À5.87 to À2.73 mmHg; P < 0.05) but not DBP (À3.6 mmHg; 95%CI, À5.14 to À2.06 mmHg) in female participants. 39 This is quite different to the findings reported by Hobbs et al, [46] [47] [48] who found beetroot bread consumption (70-100 mg) in male participants led to notable reductions in only DBP when compared with controls. In overweight and obese males, Joris et al 51 found BJ (500 mg) significantly (P < 0.05) reduced DBP but not SBP when consumed with a high-fat meal (2 muffins providing 60 g of fat)
. 51 Yet, in an RCT by Velmurugan et al, 64 a single dose of BJ providing only 372 mg of nitrate was shown to significantly reduce SBP from baseline (À7.2 mmHg; 95%CI, À12.9 to À1.4 mmHg; P ¼ 0.02), DBP from baseline (À2.6 mmHg; 95%CI, À5.4 to 0.2 mmHg; P ¼ 0.03), and DBP compared with placebo (À3.4 mmHg; 95%CI, À5.8 to À0.9 mmHg; P ¼ 0.01) in participants with hypercholesterolemia. 64 In addition, Hobbs et al 48 found significant reductions in SBP (P ¼ 0.006) and DBP (P ¼ 0.001) for up to 24 hours after BJ intakes across various doses (143 mg, 353 mg, and 707 mg). 48 However, peak reductions occurred at 2-3 hours after BJ intakes, and SBP (143 mg: À13.1 mmHg; 353 mg: À20.5 mmHg; 703 mg: À22.2 mmHg) and DBP (143 mg: À16.6 mmHg; 353 mg: À14.6 mmHg; 707 mg: À18.3 mmHg) appeared to be reduced in a dose-dependent manner. 48 Jonvik et al 50 also found that a single dose of BJ (800 mg) could significantly (P < 0.001) reduce SBP and DBP at 2.5 hours after ingestion in healthy adults. 50 However, in this 4-arm intervention trial, Jonvik et al 50 established that a single 800 mg dose of nitrate from an arugula beverage could significantly (P < 0.007) reduce SBP at 2.5 hours after consumption, and a spinach beverage could significantly (P < 0.001) reduce SBP at 5 hours after ingestion. 50 Sodium nitrate had no effect on SBP; however, all 4 nitrate interventions (NaNO 3 , BJ, rocket, and spinach) significantly reduced DBP from baseline values at 2.5 hours after consumption, an effect that remained up to 5 hours after consumption for the arugula beverage (P ¼ 0.045) and the spinach beverage (P ¼ 0.001) only. 50 Studies that investigated the acute effects of an HND (180-220 mg nitrate) from consuming vegetables such as spinach found statistically significant (P < 0.01) reductions only in SBP in healthy adults. 42, 58 Bahra et al 38 investigated the effect of KNO 3 capsules (480 mg) and reported statistically significant reductions in SBP from baseline values (À4.9 6 1.4 mmHg; P < 0.05) but not compared with placebo (À0.4 6 1.3 mmHg) or any of the DBP measurements at 3 hours after nitrate consumption. 38 Eleven studies investigated the effect of inorganic nitrate for periods of >24 hours and 20 days. Kelly et al 54 supplied older adults with BJ (595 mg/d) for 2.5 days. 54 At the end of this intervention, SBP, DBP, and MAP were significantly reduced compared with the control and placebo groups (SBP BJ: 115 6 9 mmHg; SBP control: 125 6 9 mmHg [P < 0.01]; SBP placebo: 120 6 6 mmHg [P < 63 in a 15-day BJ trial, during which BJ consumption (322 mg/d) led to significantly lowered SBP and MAP from baseline (P < 0.05) and significantly lowered DBP compared with placebo (DBP BJ: 67 6 4 mmHg; placebo: 72 6 4 mmHg; P < 0.01). 63 In a 6-day BJ (385 mg/d) trial conducted by Lansely et al, 56 only SBP was significantly reduced compared with placebo (placebo: 129 6 9 mmHg; BJ: 124 6 10 mmHg; P < 0.01). 56 However, 2 other intervention trials conducted with BJ (320-600 mg/d) for a 7-day period had no effect on BP in treated hypertensive adults or overweight and obese adults. 40, 57 Asgary et al 36 found a statistically significant reduction in SBP and DBP from baseline with cooked and raw BJ (raw BJ SBP: À6.67 mmHg, P ¼ 0.001; raw BJ DBP: À4.59 mmHg, P ¼ 0.001; cooked BJ SBP: À5.41 mmHg, P ¼ 0.001; cooked BJ DBP: À3.54 mmHg, P ¼ 0.012). 36 Whereas Sobko et al 26 found that the consumption of a traditional Japanese diet (%1140 mg/d) for 10 days led to a statistically significant reduction in DBP (À4.5 mmHg; P ¼ 0.0066), 26 Ashworth et al 37 found that in women consuming an HND (%339 6 133 mg/d) for 7 days, BP reductions were only significant for SBP (À4 6 3 mmHg; P ¼ 0.008). 37 However, Bondonno et al 41 found that the consumption of an HND (225-695 mg of nitrate/d) for 7 days in adults with high to normal BP had no statistically significant effect on reducing BP from baseline. 41 This finding is consistent with results from Miller et al 59 and Aamand et al, 35 who provided a HND (%155 mg/d) and an NaNO 3 solution (480 mg/d), respectively, for a 3-day period to healthy adults. 35, 59 DeVan et al 44 conducted a 70-day RCT, in which participants consumed either 80 mg or 160 mg of NaNO 2 each day. 44 Results from this RCT showed that long-term NaNO 2 consumption had no long-term BPlowering effect in healthy adults. 44 Rammos et al, 60 on the other hand, found a 28-day NaNO 3 (9.3 mg/kg) intervention trial in older adults could significantly lower SBP but not DBP (baseline SBP: 137 6 13 mmHg; day 28 SBP: 129 6 15 mmHg; P ¼ 0.008; baseline DBP: 80 6 9 mmHg; day 28 DBP: 79 6 9 mmHg; P ¼ 0.39). 60 This is in line with results from Jajja et al, 49 who found SBP was significantly lowered after 21 days of BJ (165 mg/d) in overweight adults (À7.3 6 5.9 mmHg; P ¼ 0.02), but no change in DBP was observed. 49 Velmurugan et al 64 also saw a statistically significant reduction in SBP (À4.1 mmHg; 95%CI, À6.8 to À1.4 mmHg; P ¼ 0.004) with BJ (372 mg/d) in adults with hypercholesterolemia over a 28-day period, an effect that did not reach significance for DBP (À1.5 mmHg; 95%CI, À3.4 to À0.3 mmHg; P ¼ 0.19). 64 However, Kapil et al 52 found BJ consumption (400 mg/d) over a 28-day period in hypertensive adults led to a statistically significant reduction in SBP (À8.1 mmHg; 95%CI: À12.4 to À3.8 mmHg; P < 0.001) and DBP (À3.8 mmHg; 95%CI: À0.7 to À6.8 mmHg; P < 0.01) compared with placebo across the intervention period 52 (Table 3) . 17, 26, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] 63, 64, 66 Endothelial function. A total of 11 studies focused on endothelial function. 17 45 This effect is supported by RodriguezMateos et al 62 in a study that identified a significant (P < 0.05) dose-dependent effect of NaNO 3 on FMD% change from baseline (1 mg/kg BW: þ0.75%; 3 mg/kg BW: þ1.1%; 8.5 mg/kg BW: þ1.7%; 10 mg/kg BW: þ2.0%). 62 Rammos et al 60 on the other hand identified that longer-term (28 days) NaNO 3 consumption (9.3 mg/ kg BW) could significantly improve FMD in older adults (nitrate: 6.5 6 0.8%; baseline: 6.0 6 0.8%, [P ¼ 0.004]; control: 6.0 6 0.8%, [P ¼ 0.0058]). 60 Bondonno et al 42 found that at 2 hours after spinach intake (180 mg/d), healthy adults experienced significantly improved FMD relative to control (þ0.5%; 95%CI, 0.1%-0.9%; P ¼ 0.01). 42 Similar results were found by Velmurugan et al 64 with a single dose of BJ (370 mg/d) in adults with hypercholesterolemia (BJ: þ1.5%; 95%CI, 0.4%-2.7%; placebo: þ0.1%, 95%CI: À0.9% to 1.1%; P ¼ 0.05). 64 Bahra et al 38 found a single dose of KNO 3 (496 mg) had no effect on FMD in healthy adults at 3 hours after nitrate consumption. 38 Yet Kapil et al 53 found a high dose of KNO 3 (1488 mg) could maintain endothelial function markedly better than a potassium chloride placebo. 53 In a 14-day BJ intervention by Asgary et al, 36 the FMD of hypertensive adults was found to be significantly higher after daily BJ treatment compared with baseline (P < 0.002); however raw BJ was significantly (P ¼ 0.007) more effective than cooked BJ at improving FMD. 36 In a 28-day trial conducted by Kapil et al, 52 BJ consumption (%400 mg/d) led to significantly increased FMD in healthy (þ1.0%; 95%CI, 0.1%-2.0%; P < 0.001) and treated hypertensive adults (þ1.1%; 95%CI, 0.1%-2.0%; P < 0.04). 52 More acutely, Webb et al 17 found that a single dose of BJ (1395 mg) could maintain endothelial function compared with the control. 17 Interestingly Joris et al 51 found that BJ consumption (500 mg) could prevent the postprandial impairment of FMD up to 2 hours after a mixed meal containing approximately 60 g of fat (BJ: À0.37% 6 2.92%; control: À1.56% 6 2.90%; P ¼ 0.03). 51 (Table 4) . 17, 36, 38, 42, 45, [51] [52] [53] 60, 62, 64 Arterial stiffness. A total of 10 studies focused on arterial stiffness. 38, 41, 44, 47, 51, 52, 55, 57, 60, 64 Two studies found that a single dose of BJ (%370-800 mg) could significantly reduce arterial stiffness, as indicated by significant reductions in PWV (approximately À0.4 m/s; P < 0.03) and/or AIx (À2.5%; P ¼ 0.01) at 3 hours after BJ ingestion. 55, 64 This was not a consistent finding across the literature, with 2 studies failing to produce a notable reduction in PWV or AIx after the acute consumption of BJ (70-500 mg) in relatively healthy adults. 47, 51 A high intake of dietary nitrate for a 7-day period also failed to alter PWV or AIx. 41 ,57 Yet, Bahra et al 38 found that KNO 3 supplementation (496 mg/d) in healthy adults for a 3-day period led to statistically significant reductions in aortic PWV (baseline aortic PWV: 6.5 6 0.1 m/s; post-KNO 3 aortic PWV: 6.2 6 0.1; P < 0.001). 38 On the other hand, 2 longer-term studies (3-6 wk) found BJ consumption (%370-390 mg/d) could markedly reduce PWV and AIx compared with placebo. 52, 64 However, in a 10-week study by DeVan et al, 44 NaNO 2 (80-160 mg/d) consumption did not reduce arterial stiffness in healthy, older adults 44 (Table 5) . 61 a single dose of KNO 3 (125 mg) was shown to inhibit platelet activity by 30.9% (95%CI, À39.2% to À22.7%; P < 0.001) in healthy adults. 61 Velmurugan et al 65 discovered a potential sexdependent effect of a single dose of KNO 3 (496 mg) on platelet activity, with platelet activity supressed only in male participants. 65 Long-term consumption (6 wk) of BJ (320 mg/d) was shown to significantly (P ¼ 0.02) reduce platelet activity (À16%) compared with placebo in adults with hypercholesterolemia 64 (Table 6) . 61, 64, 65 Blood lipids. A total of 4 studies focused on blood lipids. 36, 47, 51, 64 A single serving of beetroot (70-500 mg) did not appear to have any effect on plasma TG or LDL cholesterol. 47, 51, 64 In addition, no blood lipid changes were seen at the end of a 6-week BJ (372 mg/d) intervention in adults experiencing hypercholesterolemia. 64 However, in hypertensive adults, 14 days of BJ consumption led to significant reductions in plasma cholesterol (baseline: 189.96 6 33.06 mg dL; BJ: 169.96 6 36.23 mg dL; P ¼ 0.002) and LDL concentrations from baseline (baseline: 117.67 6 24.35 mg dL; BJ: 103.08 6 25.11 mg dL; P ¼ 0.001) 36 (Table 7) . 36, 47, 51, 64 Effect of Ix on platelet monocyte aggregation vs placebo. Reduction in platelet monocyte aggregation of %10% with Ix vs placebo (P ¼ 0.02) Abbreviations: ADP, adenosine diphosphate; BJ: beetroot juice; cGMP, cyclic guanosine monophosphate (inhibitor of platelet aggregation); Ix, intervention; KCl, potassium chloride; KNO 3, potassium nitrate; NO 3 , nitrate; P-selectin, activator of platelet aggregation. Subgroup analyses by source of inorganic nitrate revealed that KNO 3 led to the greatest reduction in resting SBP (À7.06 mmHg; 95%CI, À11.86 to À2.26; P ¼ 0.004), followed by BJ (À5.67 mmHg; 95%CI, À7.46 to À3.89; P < 0.0001) and an HND (À2.38 mmHg; 95%CI, À5.81 to 1.04; P ¼ 0.173) ( Figure S7 in the Supporting Information online). For resting DBP, BJ consumption led to significantly greater reductions in BP (À2.36 mmHg; 95%CI, À3.54 to À1.18; P < 0.0001) than an HND (À0.60 mmHg; 95%CI, À2.40 to 1.21; P ¼ 0.518) ( Figure S8 in the Supporting Information online).
Meta-regression analysis revealed that the dose of inorganic nitrate was significantly associated with resting SBP (P ¼ 0.031) ( Figure S9 in the Supporting Information online) but not resting DBP (P ¼ 0.315) ( Figure S10 in the Supporting Information online). Although subgroup analysis found that doses of inorganic nitrate of 650 mg/day or more led to the greatest reductions in resting SBP (À10.45 mmHg; 95%CI, À15.42 to À5.47; P < 0.0001), as little as 130-259 mg/day (À5.52 mmHg; 95%CI, À9.54 to À1.50; P ¼ 0.007) and 260-398 mg/day (À4.45 mmHg; 95%CI, À6.40 to À2.52; P < 0.0001) were found to significantly reduce resting SBP ( Figure S11 in the Supporting Information online). Resting DBP was only significantly reduced at doses of 130-259 mg (À2.62 mmHg; 95%CI, À4.24 to À1.00; P ¼ 0.002) or at doses much higher (!650 mg: À6.31 mmHg; 95%CI, À12.49 to À0.14; P ¼ 0.045) ( Figure S12 in the Supporting Information online).
Meta-regression analysis did not reveal any notable associations with study participant characteristics such as mean age (y), ratio of male participants, or mean BMI for resting or ambulatory SBP. Resting DBP was significantly associated with the ratio of male participants in the study population (P ¼ 0.031; adjusted R 2 ¼ 100%) ( Figure S13 in the Supporting Information online), an association that was nearly significant for ambulatory DBP (P ¼ 0.086) ( Figure S14 in the Supporting Information online). Ambulatory DBP was also significantly associated with the mean BMI of study participants (P ¼ 0.047) ( Figure S15 in the Supporting Information online), in that the level of DBP reduction tended to be smaller if the BMI of study participants was higher. Year of study publication was significantly associated with the effect size of inorganic nitrate consumption for both resting SBP (P ¼ 0.025) ( Figure S16 in the Supporting Information online) and DBP (P ¼ 0.032) ( Figure S17 in the Supporting Information online), in that the effect size tended to be smaller as the year of publication increased. Yet, this finding could be linked to study quality ratings, in that studies of a neutral quality rating found greater effect sizes (SBP: À6.65 mmHg; 95%CI, À10.01 to À3.29; P < 0.0001; DBP: À3.94 mmHg; 95%CI, À6.72 to À1.16; P ¼ 0.005) than the studies of a positive quality rating (SBP: À3.92 mmHg; 95%CI, À5.87 to À1.99; P < 0.0001; DBP: À1.42 mmHg; 95%CI, À2.48 to À0.37; P ¼ 0.008) (Figures S18 and S19 in the Supporting Information online) for resting BP, a finding not consistent with ambulatory BP findings.
Flow-mediated dilatation. Overall inorganic nitrate consumption was associated with a significantly raised FMD (0.59%; 95%CI, 0.32%-0.86%; P < 0.0001; I 2 ¼ 54.9%) compared with control or placebo ( Figure 4) . 17, 38, 42, [51] [52] [53] 60, 64 Beetroot juice led to the greatest increase in FMD (0.84%; 95%CI, 0.48%-1.20%; P < 0.0001) followed by an HND (0.5%; 95%CI, 0.11%-0.89%; P ¼ 0.012), NaNO 3 (0.5%; 95%CI, À0.11% to 1.11%; P ¼ 0.112), and KNO 3 (0.27%; 95%CI, 0.13%-0.42%; P < 0.0001) supplement ( Figure S20 in the Supporting Information online). However, metaregression analysis revealed that the effect size of FMD% was not significantly associated with the dose of nitrate supplementation (P ¼ 0.557) ( Figure S21 in the Supporting Information online).
Subgroup analysis found inorganic nitrate consumption increased FMD to a greater extent in a patient population (0.72%; 95%CI, 0.35%-1.10%; P < 0.0001) compared with a healthy population (0.54%; 95%CI, 0.20%-0.88%; P ¼ 0.002) ( Figure S22 in the Supporting Information online). These findings correspond with the meta-regression analysis, as the effect of inorganic nitrate on FMD tended to be greater as the mean BMI of participants increased (P ¼ 0.031) ( Figure S23 in the Supporting Information online) and as the age of study participants increased (P ¼ 0.008) ( Figure S24 in the Supporting Information online). Studies rated as positive in quality tended to find larger effect sizes for FMD (0.69%; 95%CI, 0.70%-1.10%; P ¼ 0.001) compared with studies rated as neutral in quality (0.45%; 95%CI, 0.04%-0.85%; P ¼ 0.032) ( Figure S25 in the Supporting Information online).
Arterial stiffness. Overall, inorganic nitrate intakes were significantly associated with reduced arterial stiffness measurements, including PWV (À0.23 m/s; 95%CI, À0.35 to À0.1; P < 0.0001; I 2 ¼ 12.6%) ( Figure 5 ) 38 Platelet aggregation. Pooled nitrate intakes (from inorganic salts and BJ) was associated with an 18.9% reduction in platelet aggregation (95%CI, À26.5% to À11.3%; P < 0.0001; I 2 ¼ 25.0%) in response to platelet agonists ( Figure 7) . 61, 64, 65 Although ambulatory SBP appears to have more studies published toward the null side of the mean effect size, this is unlikely to represent publication bias ( Figure S31 in the Supporting Information online).The funnel plot for FMD%, on the other hand, indicates a potential presence of publication bias, given that 7 of 9 studies sit on the treatment effect side of the mean effect size ( Figure  S32 in the Supporting Information online). The asymmetry in the contour-enhanced funnel plot for FMD% indicates the absence of negative studies ( Figure S33 in the Supporting Information online). However, the regions of missing studies do not appear to be dependent on statistical significance, indicating that publication bias is unlikely to be responsible for this asymmetry. Relatively high heterogeneity and low number of studies might explain the asymmetry. Potential sources of between-study heterogeneity for BP and FMD were explored (Tables  S9-S13 in the Supporting Information online) .
DISCUSSION
This review systematically assessed the literature and identified that acute intakes of inorganic nitrate significantly (P 0.05) lower resting BP, reduce arterial stiffness and platelet aggregation, and improve endothelial function, all major risk factors for the development of atherosclerosis and CVD. [68] [69] [70] The primary outcome, BP, was the most commonly measured outcome reported across the literature. Although BP was previously investigated in a metaanalysis by Siervo et al, 71 a substantial amount of research has been published since its publication in 2013, indicating the need for an up-to-date analysis. [35] [36] [37] 40, 41, 44, 49, 50, 52, 55, 57, 60, 64, 66 Similar to Siervo et al, 71 this review included intervention studies in which inorganic salts (NaNO 3 , KNO 3 ) and BJ were provided; however, in contrast to the previous review, this review also included studies in which HNDs were prescribed. 26, 37, 41, 42, 58, 59 This is an important inclusion given that HNDs are a more "real-world" example of how nitrate is consumed in the general population.
It is worth noting that the pooled resting SBP findings were consistent with Siervo et al 71 (À4.80 mmHg vs À4.4 mmHg, respectively); however, a statistically significant (P 0.0001) reduction in resting DBP was also detected (À1.74 mmHg vs À1.1 mmHg, respectively), an outcome that was not statistically significant (P ¼ 0.06) for Siervo et al. 71 Further, findings from the current analysis provide promising evidence to support the role of inorganic nitrate for reducing CVD given that a 5-mmHg reduction in SBP and 2-mmHg reduction in DBP has been estimated to reduce the prevalence of hypertension by 20% and is believed to result in 14% fewer deaths from stroke, 9% fewer deaths from coronary heart disease, and 7% fewer deaths overall. 72 Current national dietary guidelines for reducing hypertension tend to focus on reducing sodium intakes and promoting the consumption of diets rich in fruits and vegetables. 73, 74 The current meta-analysis found that inorganic nitrate consumption can reduce resting BPs by a similar amount to those reportedly achieved with reduced sodium intakes. 72 Just 1 serving (%130-259 mg) of BJ was found to be a safe and highly effective method for reducing resting BP and could represent a promising basis for making more specific dietary recommendations for hypertension prevention. However, the impact of an HND containing green leafy vegetables for reduced BP is currently unconvincing. This may be linked to the high variability of nitrate contents seen in green leafy vegetables, which can alter considerably depending on cultivation, cooking, and processing practices. 75, 76 By comparison, a prospective cohort study (n ¼ 1544) by Golzarland et al 77 identified a 37% reduction in 3-year risk of hypertension in adults with a higher intake of nitrate-containing vegetables. 77 These results indicate a promising long-term effect of HNDs, given that hypertension is responsible for approximately 13% of global deaths each year and is a major risk factor for cardiovascular morbidity and mortality; however further investigation is warranted to confirm this finding. 78 Subgroup analysis revealed inorganic nitrate consumption led to greater reductions in resting BP for healthy participants compared with patient groups. Meta-regression analyses revealed BP effect sizes were not associated with the mean age or mean BMI of study participants. Resting DBP reductions were significantly (P ¼ 0.031) associated with an increased number of male participants, a trend that almost reached statistical significance (P ¼ 0.086) for ambulatory DBP, which indicates a potential sex-dependent effect. This sex difference could in part be explained by a naturally greater vascular production of NO by premenopausal women because estrogen has been shown to enhance the release and activity of NO. 79, 80 Therefore, males may benefit more from the rise in plasma nitrate/nitrite from dietary sources because it may enhance the NO donor availability in males to a greater extent than in females.
Ambulatory BP monitoring involves measuring BP at regular intervals over an extended period (usually 24 h) while patients undergo normal daily activities. 81 One of the major benefits of ambulatory BP monitoring is that it is not influenced by the white-coat effect (the notion that BPs are higher when taken in a medical setting). 81 It was therefore interesting to note that dietary nitrate intakes appeared to have a greater effect on lowering resting BP than ambulatory BP. This finding could be linked to the fact that, after a dietary nitrate load, the plasma levels of nitrate can rise for up to 5-6 hours after ingestion and represent a period of time in which you could expect to see BP changes due to NO activity. 17, 82 After this point, however, plasma nitrate levels will rapidly diminish, along with any beneficial effects, unless these plasma levels are replenished by another dietary nitrate load. 17 It would be interesting to know whether these larger periodic reductions in resting BP or small reductions in ambulatory BP could be clinically relevant and reduce CVD morbidity or mortality in the long term.
To the authors' knowledge, this is the first systematic review to quantify the effect of inorganic nitrate consumption on FMD, PWV, AIx, and platelet activity. Previously it was found that for every 1% increase in FMD there was a 10% reduced risk of CVD. 83 The results from the current review indicate that inorganic nitrate consumption (especially BJ: 0.84%; 95%CI, 0.48-1.20, P < 0.0001) can significantly improve FMD% (overall: 0.59%; 95%CI, 0.32%-0.86%; P < 0.0001), particularly in patient populations (patients: 0.72%; 95%CI, 0.35%-1.10%; P < 0.0001). In addition, the beneficial effects of inorganic nitrate for FMD were significantly associated with a higher BMI (P ¼ 0.031) and age (P ¼ 0.008). Previous studies have shown that baseline FMD% levels are inversely related to effect size, indicating that interventions targeting FMD% are more effective at restoring the dysfunctional endothelium of patient, overweight/obese, and older participants, rather than improving normal endothelial function in healthy participants. 84 The findings indicate that inorganic nitrate consumption led to significantly reduced arterial stiffness, indicated by a pooled reduction in AIx (À2.1%; 95%CI, À4.2% to 0.003%) and PWV (À0.23 m/s, 95%CI, À0.35 to À0.1), an effect wthat could be linked to FMD, given that arterial stiffness was also improved to a greater extent in patient populations rather than healthy populations. The pooled analysis also found that inorganic nitrate consumption significantly reduced platelet aggregation by 18.9% (95%CI, À26.5% to À11.3%; P < 0.0001) in response to platelet agonists. 61, 64, 65 It is important to mention, however, that platelet aggregation was measured only in response to either KNO 3 or BJ; therefore these findings are not directly applicable to a HND, especially given that HNDs are generally high in green leafy vegetables, which are also a rich source of vitamin K, which can induce the blood clotting cascade. 85 Further, the qualitative results indicate there was no effect of inorganic nitrate on plasma lipids. These results make sense within the established context of NO's role in vascular homeostasis. For example, NO has a major role in regulating endothelial function, vasodilation, arterial stiffness, and blood clotting; however, no such function has been linked to blood lipid regulation. 86 These CVD risk factors are clearly interdependent, in that endothelial dysfunction leads to increased arterial stiffness and BP, leading to increased vascular damage, inflammation, platelet aggregation, and possibly dislipidemia. 4, 87, 88 Although the review findings represent the effect of short-term nitrate intakes on CVD risk factors, it would be reasonable to hypothesize that an increased longterm consumption of dietary nitrate would lead to a reduced risk of atherosclerosis and CVD. 88 This concept was recently explored for the first time by Blekkenhorst et al 89 89 Although these results are promising, it is clear additional longitudinal investigation is required to clearly elucidate the long-term effects of nitrate consumption for the prevention of atherosclerosis and CVD.
Strengths, limitations, and potential sources of bias
This systematic review and meta-analysis has several limitations. Most important is that current available literature in this field reflects studies conducted in small population groups, over short periods of time, across a variety of interventions to which large heterogeneity was present. Although BP and FMD are common measurements, there are many technical factors that can influence the reproducibility and interpretation of results. 90, 91 In addition, the strength of these findings may be limited given the variability of study quality, as a number of included studies had poorly described methodology or provided limited details for at least 1 outcome. However, this issue was addressed through the use of a random-effects model meta-analysis. Only 3 studies were included in the platelet aggregation meta-analysis, making heterogeneity and bias difficult to estimate; thus, these results should be interpreted with care. In addition, given the low number of studies included for meta-regression analyses, caution should be taken when interpreting nonsignificant findings.
As previously mentioned, there was considerable heterogeneity across the type of interventions (NaNO 2 / NaNO 3 /KNO 3 /BJ/HND) studied, and control/placebo groups. For example, BJ interventions were compared with anything from nitrate-depleted BJ to fruit juice or water. For NaNO 2 /NO 3 interventions a sodium chloride (NaCl) placebo was frequently used. This was an unexpected choice for placebo when BP was a study outcome, as it is well established in the literature that excessive intakes of NaCl are associated with an increase in BP or worsening of hypertension. 92 This indicates that more careful consideration of appropriate control/placebo in these studies is required, and choice of control/placebo could act as a large source of bias.
The major strength of this systematic review is the unbiased, comprehensive, and critical evaluation of the available literature. With the exception of a few small and now outdated systematic reviews, this area of literature has not been reviewed in accordance with established systematic review protocols, 93 and cherry-picking of literature has been prominent. In addition, this review provides an exceptionally comprehensive overview of the current available literature, from which the meta-analysis was able to detect clinically relevant effects.
CONCLUSION
Hypertension has long been a major public health target for reducing CVD events, but it is increasingly clear that targeting of multiple CVD risk factors is required to adequately address this multifactorial disease. It is therefore important to note that, in addition to a notable BP-lowering effect, inorganic nitrate intakes were found to improve endothelial function, reduce platelet aggregation, and reduce arterial stiffness, all of which are major risk factors for the development of atherosclerosis, coronary artery disease, and myocardial infarction. Despite the literature indicating a clear beneficial effect of inorganic nitrate intakes for improving CVD risk factors, increased epidemiological investigation is required to understand its long-term role in reducing CVD events, including myocardial infarction and mortality. This is a worthwhile line of investigation given that inorganic nitrate consumption from vegetable sources represents a relatively simple and cost-effective strategy for targeting CVD at a population level.
Acknowledgments
Author contributions. The authors' responsibilities were as follows: J.K.J., A.J.P., L.K.M-W., and M.A.M. designed the research question and methodology; J.K.J. conducted the search; J.K.J. and M.A.M. screened titles and abstracts, and conducted data extraction; J.K.J., A.J.P., and L.K.M-W. assessed the methodological quality of included studies; J.K.J. and C.O. conducted the meta-analysis; J.K.J. wrote the manuscript and had primary responsibility for the final content of the manuscript. All authors read and approved the final manuscript.
Funding. This study was not supported by external funding sources.
Declaration of Interest. The authors have no relevant interests to declare.
Supporting Information
The following Supporting Information is available through the online version of this article at the publisher's website. 
